ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1047
0,00%
Bitcoin
66.869,04
-0,32%
Brent Oil
83,76
0,00%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Akebia Therapeutics Inc (AKBA)

  7. Akebia Therapeutics Inc (AKBA) Notícias

AKBA

Akebia Therapeutics (AKBA)

Akebia Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:AKBA
DataHoraFonteTítuloCódigoCompanhia
14/05/202417:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKBAAkebia Therapeutics Inc
14/05/202409:00PR Newswire (US)Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor ConferenceNASDAQ:AKBAAkebia Therapeutics Inc
13/05/202420:19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AKBAAkebia Therapeutics Inc
09/05/202408:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AKBAAkebia Therapeutics Inc
09/05/202408:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKBAAkebia Therapeutics Inc
09/05/202408:00PR Newswire (US)Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:AKBAAkebia Therapeutics Inc
02/05/202409:30PR Newswire (US)Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business HighlightsNASDAQ:AKBAAkebia Therapeutics Inc
01/05/202417:05PR Newswire (US)Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:AKBAAkebia Therapeutics Inc
27/03/202421:26PR Newswire (US)Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on DialysisNASDAQ:AKBAAkebia Therapeutics Inc
14/03/202417:15PR Newswire (US)Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:AKBAAkebia Therapeutics Inc
11/03/202418:05PR Newswire (US)Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:AKBAAkebia Therapeutics Inc
30/01/202418:33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AKBAAkebia Therapeutics Inc
30/01/202410:00PR Newswire (US)Akebia Secures $55 Million Term Loan FinancingNASDAQ:AKBAAkebia Therapeutics Inc
18/01/202419:21Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AKBAAkebia Therapeutics Inc
09/01/202410:30PR Newswire (US)Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial OfficerNASDAQ:AKBAAkebia Therapeutics Inc
20/12/202310:00PR Newswire (US)Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:AKBAAkebia Therapeutics Inc
20/11/202310:00PR Newswire (US)Akebia Therapeutics to Present at Piper Sandler Healthcare ConferenceNASDAQ:AKBAAkebia Therapeutics Inc
08/11/202309:30PR Newswire (US)Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:AKBAAkebia Therapeutics Inc
02/11/202317:30PR Newswire (US)Akebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon AdvisorsNASDAQ:AKBAAkebia Therapeutics Inc
31/10/202309:00PR Newswire (US)Akebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business HighlightsNASDAQ:AKBAAkebia Therapeutics Inc
25/10/202309:30PR Newswire (US)Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney DiseaseNASDAQ:AKBAAkebia Therapeutics Inc
18/10/202309:00PR Newswire (US)Akebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023NASDAQ:AKBAAkebia Therapeutics Inc
28/09/202309:00PR Newswire (US)Akebia Therapeutics Resubmits New Drug Application to the FDA for VadadustatNASDAQ:AKBAAkebia Therapeutics Inc
26/09/202309:00PR Newswire (US)Akebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial UpdateNASDAQ:AKBAAkebia Therapeutics Inc
06/09/202309:00PR Newswire (US)Akebia Therapeutics to Present at H.C. Wainwright Global Investment ConferenceNASDAQ:AKBAAkebia Therapeutics Inc
28/08/202309:55Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:AKBAAkebia Therapeutics Inc
25/08/202309:09PR Newswire (US)Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:AKBAAkebia Therapeutics Inc
24/08/202309:00PR Newswire (US)Akebia Therapeutics Expects to Resubmit Vadadustat NDA in Third Quarter 2023NASDAQ:AKBAAkebia Therapeutics Inc
23/08/202317:35PR Newswire (US)Akebia Therapeutics to Report Second Quarter Financial Results and Discuss Recent Business HighlightsNASDAQ:AKBAAkebia Therapeutics Inc
17/08/202317:05PR Newswire (US)Akebia Therapeutics to Report Second Quarter Financial Results by August 25, 2023NASDAQ:AKBAAkebia Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:AKBA

Seu Histórico Recente

USOTC
PIAC
Princeton Capital (PK)
LSE
0EN5
Hanseyachts
BMF
FRCF34
FRCF34 - 01/2034
LSE
0J75
Fleury Michon
AMEX
BSDE
Invesco Bulletshares 202...
EU
P988S
P988S
COIN
YFIWUSD
YFIW.FINANCE
EU
N653S
N653S
ASX
NAV
Navigator Resources
COIN
LIRUSD
COIN
CACHBTC
USOTC
AAUGF
Aero Energy (PK)
DBI
4N96
DAXsubsector All Interne...
COIN
EBLUUSD
LSE
ENKA
NYSE
XCT
Equity Securities Trust I
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados